Defy Your DNA. Published 2013 by Ten Finger Press.

Full papers (Links provided):

1. A meta-analysis of increasing inhaled steroid or adding salmeterol in symptomatic asthma (MIASMA). Br Med J 2000; 320: 1368 – 1372. [Authors: Shrewsbury SB, Pyke S, Brittain MG]

2. Salmeterol in paediatric asthma. Thorax 2000; 55: 780-784 [Authors: Byrne C, Bush A, Barnes P, Shrewsbury SB]

3. Salmeterol 100mcg: An analysis of its tolerability in single and chronic dose studies. Annals All Asthma Immunol 2001; 87: 465-473 [Authors: Shrewsbury SB, Hallett C]

4. Systematic review – a tool for the pharmaceutical physician. Int J Pharm Med 2002; 16: 67- 70 [Author: Shrewsbury SB]

5. Potential Effects of Fluticasone Propionate on Bone Mineral Density in Patients With Asthma: A 2-Year Randomized, Double-Blind, Placebo-Controlled Trial. Mayo Clin Proc 2004; 79: 458-466 [Authors: Kemp J, et al Shrewsbury S]

6. Effect of Dry Powder Inhaler Resistance on the Inspiratory Flow Rates and Volumes of Cystic Fibrosis Patients of Six Years and Older. J Aerosol Med 2006; 19 (4): 456-465 [Authors: Tiddens HAWM, et al Shrewsbury SB]

7. Aerosol Delivery of Ergotamine Tartrate via a Novel Inhaler (Tempo™ ET) in Humans. Curr Med Res Op 2007; 23: 3177-3187 [Authors: Armer TA, Shrewsbury SB, Newman SP, Pitcairn G, Ramadan N]

8. Safety and Pharmacokinetics of Dihydroergotamine Mesylate Administered via a Novel (Tempo™) Inhaler. Headache 2008; 48(3): 355-367 [Authors: Shrewsbury SB, Cook RO, Edwards C, Taylor G, Ramadan N]

9. Breath synchronous plume-control inhaler for pulmonary delivery of fluticasone propionate. Int J Pharmaceutics 2008; 356: 137-143 [Authors: Shrewsbury SB, Armer TA, Newman SP, Pitcairn G]

10. Intrapulmonary and Intravenous Administrations of Dihydroergotamine Mesylate (DHE) Have Similar Cardiovascular Effects in the Conscious Dog. Br J Pharmacology 2008; 154: 1254-1265 [Authors: Shrewsbury SB, Stonerook M, Okikawa JK]

11. Randomized, Double Blind, Placebo Controlled Study of MAP0004 (Orally-inhaled DHE) in Adult Asthmatics. Curr Med Res Op 2008; 24(7): 1977-1985 [Authors: Shrewsbury SB, Kori S, Miller D, Pedinoff A, Weinstein S]

12. Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. Int J Pharmaceutics 2009; 365: 12–17 [Authors: Shrewsbury SB, Bosco A, Uster P]

13. A Randomized, Double Blind, Placebo-Controlled Study of MAP0004 in Adult Patients with Migraine. Headache 2009; 49: 826-837 [Authors: Aurora SK, Rozen TD, Kori SH, Shrewsbury SB]

14. Reduced Adverse Event Profile of Orally Inhaled DHE (MAP0004) vs IV DHE: Potential Mechanism. Headache 2009; 49: 1423-1434 [Authors: Cook RO, Shrewsbury SB, Ramadan NM]

15. Safety Pharmacology and Genetic Toxicity Evaluation of AVI-4658, a novel Exon Skipping Phosphorodiamidate Morpholino Oligomer (PMO) for the Treatment of Duchenne Muscular Dystrophy. Int J Toxicol 2010; 29: 143-156 [Authors: Sazani P, Weller D, Shrewsbury SB]

16. Repeat Dose Toxicology Evaluation in Cynomolgus Monkeys of AVI-4658, a Phosphorodiamidate Morpholino Oligomer (PMO) Drug for the Treatment of Duchenne Muscular Dystrophy. Int J Toxicol 2011; doi: 10.1177/1091581811403505 [Authors: Sazani P, Van Ness KP, Weller DL, Poage D, Palyada K, Shrewsbury SB]

17. Chemical and Mechanistic Toxicology Evaluation of Exon Skipping Phosphorodiamidate Morpholino Oligomers in mdx mice. Int J Toxicol 2011; doi: 10.1177/1091581811403504 [Authors: Sazani P, Van Ness K, Weller DL, Poage D, Nelson K, Shrewsbury SB]

18. Exon skipping and dystrophin restoration in Duchenne Muscular Dystrophy patients after systemic phosphorodiamidate morpholino oligomer treatment. Lancet 2011; 378: 595-605 [Authors: Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, Abbs S, Garralda ME, Bourke J, Wells DJ, Dickson G, Wood MJA, Wilton SD, Straub V, Shrewsbury SB, Sewry C, Morgan JE, Bushby K, Muntoni F]

19. Clinical Expert Panel on Monitoring Potential Lung Toxicity of Inhaled Oligonucleotides: Consensus Points and Recommendations. Nucleic Acid Technology 2012; 22(4): 246-254 [Authors: Alton EW, Boushey HA, Garn H, Green FH, Hodges M, Martin RJ, Murdoch M, Renz H, Shrewsbury SB, Seguin R, Johnson G, Parry J, Tepper J, Renzi P, Cavagnaro J, Ferrari N]

20. The Oligonucleotide Safety Working Group [Invited editorial]. Nucleic Acid Technology 2012; 22(4): 211-212 [Authors: Schubert D, Levin AA, Kornbrust D, Cavagnaro JA, Berman CL, Henry S, Seguin R, Ferrari N, Shrewsbury SB]

21. The Leadership Study: A Phase 2 Study to Evaluate the Efficacy and Safety of the Novel, Oral SHIP1 Activator, AQX-1125, in Subjects with Moderate to Severe Interstitial Cystitis/Bladder Pain Syndrome. J.Urology 2016; 196: 747-754. [Authors: Nickel JC, Egerdie B, Davis E, Evans R, Mackenzie L,Shrewsbury SB]

22. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD®) Device, in Healthy Adult Subjects. Headache 2019; 59(3): 394-409. [Authors: Shrewsbury SB, Jeleva M, Satterly KH, Lickliter J, Hoekman J]

23. Dihydroergotamine (DHE) – Then and Now: A Narrative Review. Headache 2020; 60(1):40-57 [Authors: Silberstein SD, Shrewsbury SB, Hoekman J]

24. SNAP 101: Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of INP105 (nasal olanzapine) in Healthy Adults. J Clin Psych 2020;81(4):12-20 [Authors: Shrewsbury SB, Hocevar-Trnka J, Satterly KH, Craig KL, Lickliter JD, Hoekman J.]

25. The Upper Nasal Space: A Novel Delivery Route Ideal for CNS Drugs. US Neurology. 2020;16(1):25-31 [Authors: Hoekman J, Ray S, Aurora SK, Shrewsbury SB]

26. A Link Between Gastrointestinal Disorders and Migraine: Insights into the Gut-Brain Connection. Headache 2021; DOI:10.1111/head.14099 [Authors: Aurora SK, Shrewsbury SB, Ray S, Hindiyeh N, Nguyen L]

27. Drug delivery via the Upper Nasal Space: A novel route for Anesthesiologists, Intensivists and Emergency Room Physicians? J Clin Anesth Intensive Care 2021; 2(1):8-14 [Authors: Shrewsbury SB, Hocevar-Trnka J, Hoekman J]

28. The Upper Nasal Space: A Novel, Efficient Route for Systemic Drug Delivery. Respiratory Drug Delivery 2021; 1:117-126 [Authors: Shrewsbury SB, Ray S, Fuller C, Hoekman J]

29. Nasal Delivery of Acute Medications for Migraine: The Upper Versus Lower Nasal Space. J Clin Med 2021; 10(11): DOI: 10.3390/jcm.10112468 [Authors: Martin V, Hoekman J, Aurora SK, Shrewsbury SB]

30. STOP 301: A Phase 3, Open-label Study of Safety, Tolerability and Exploratory Efficacy of INP104, Precision Olfactory Delivery (POD®) of Dihydroergotamine Mesylate over 24/52 Weeks in Acute Treatment of Migraine Attacks in Adult patients. Headache 2021; 61(8):1214-1226 [Authors: Smith TR, Winner P, Aurora SK, Jeleva MD, Hocevar-Trnka J, Shrewsbury SB]

31. Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action. Journal of Aerosol Medicine; 2022;35(6): [Authors: Cooper W; Shrewsbury SB; Ray S; Aurora SK; Fuller C; Davies G; Hoekman J]

32. Variability in Recurrence Rates with Acute Treatments for Migraine: Why Recurrence Is Not an Appropriate Outcome Measure. Journal of Headache and Pain. 2022;23:148:doi 10.1186/s1094-01519-4 [Authors: Tepper SJ; Ailani J; Ray S; Hirman J; Shrewsbury SB; Aurora SK]

33. The Pharmacokinetics of Drug Delivery to the Upper Nasal Space: A Review of INP105 Development. Medical Research Archives 2022;10(9):doi 10.18103/mra.v10i9.2971. [Authors: Shrewsbury SB, Davies G, McConnachie L, Hoekman J]

34. The Upper Nasal Space as a Promising New Route for Drug Administration: Implications for Nasal Safety Assessments from the Pivotal STOP 301 Study of INP104. Annals of Otolaryngology & Rhinology 2022;9(5):1303 [Authors: Davis G, Pransky S, Fatakia A, Shrewsbury SB]

35. Trends and Advancements in Drug Delivery: What is the “perfect” method of drug delivery? Medical Research Archives 2022;10(10):doi 10.18103/mra.v10i10.3218 [Author: Shrewsbury SB]

36. New Characterization of Dihydroergotamine Receptor Pharmacology in the Context of Migraine: Utilization of a beta-arrestin Recruitment Assay. Frontiers in Neurology 2023;  [Authors: McConnachie L, Goadsby PJ, Fitzpatrick CJ, Ray S, Shrewsbury SB, Aurora SK]

37. Safety, Tolerability and Effectiveness of Repetitive IV Dihydroergotamine for Refractory Chronic Migraine with Cardiovascular Risk Factors – a Retrospective StudyHeadache  [Wang VS, Kosman J, Yuan H, Lauritsen C, Shrewsbury S, Aurora S, Hopkins M, Silberstein S]

38. INP104: A Drug Evaluation of a Nonoral Product for the Acute Treatment of Migraine. Pain Management [Starling AJ, Mallick-Searle T, Aurora SK, Shrewsbury SB]

39. The Upper Nasal Space: Option for Systemic Drug Delivery, Mucosal Vaccines and “Nose-to-Brain”. Pharmaceutics 2023;15: pharmaceutics15061720 [Shrewsbury SB]

40. The Pharmacokinetics of Drugs Delivered to the Upper Nasal SpacePharmaceutical Medicine 2023 Aug doi: 10.1007/s40290-023-00495-7. [Shrewsbury SB] 

Abstracts and Posters: (as of March 2023), 188 and counting on the following topics:

Healthcare logistics
Respiratory disease (Asthma, COPD, CF, Bronchiectasis, Lung transplant rejection)
Quality of Life Questionnaire development
Meta-analyses and systematic reviews
Lung function testing
Novel inhaler and nasal delivery devices
Receptor research
Inhaled particle engineering
Toxicology – inhaled and systemic
Safety pharmacology
Emerging infectious disease(s)
Neuromuscular disease
West Nile Virus
Orphan Drugs/Rare Diseases
Headache medicine and migraine treatment

In the following journals:

American Journal of Respiratory and Critical Care Medicine
American Journal of Transplantation
Annals of Allergy, Asthma and Immunology
Annals of Otolaryngology & Rhinology
British Medical Journal
European Respiratory Journal

Frontiers in Neurology
Indian Academy of Pediatrics
International Journal of Heart Lung Transplantation
Journal of Aerosol Medicine
Journal of Allergy and Clinical Immunology
Journal of Clinical Medicine
Medical Research Archives
Neuromuscular Disorders
Pediatric Pulmonology


Pharmaceutical Medicine
Proceedings of the American Thoracic Society
Respiratory Drug Delivery Proceedings

and presented at these meetings:

American Academy of Allergy, Asthma and Immunology
American Academy of Neurology
American College of Neuropsychopharmacology
American College of Allergy, Asthma and Immunology
American College of Chest Physicians
American Headache Society
American Psychiatric Association
American Thoracic Society
American Urology Association
British Thoracic Society
North American Cystic Fibrosis meeting
European Congress of Clinical Microbiology and Infectious Disease
European Respiratory Society
European Society of Medicine
European Society for the Study of Interstitial Cystitis
International Conference Neuromuscular Disorders
International Society for Aerosols in Medicine
International Society for Heart Lung Transplantation
Medical Research Council meeting on Translational Medicine in Neuromuscular disease
Respiratory Drug Delivery
World Asthma Meeting
World Muscle Society
Annual Congress on Rare Disease and Orphan Drugs

Scroll to Top